HRT Financial’s Avadel Pharmaceuticals AVDL Stock Holding History

HRT Financial’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-117,259	Closed	-$2.53M	–	3767
2025 Q4	$2.53M	Buy	+117,259	New	+$2.28M	0.01%	1149
2025 Q2	–	Sell	-64,454	Closed	-$504K	–	2589
2025 Q1	$504K	Buy	+64,454	New	+$540K	﹤0.01%	1460
2021 Q4	–	Sell	-13,728	Closed	-$134K	–	3168
2021 Q3	$134K	Sell	13,728 -42,373	-76%	-$334K	﹤0.01%	2817
2021 Q2	$377K	Buy	56,101 +42,581	+315%	+$338K	﹤0.01%	1995
2021 Q1	$122K	Buy	+13,520	New	+$109K	﹤0.01%	2427
2020 Q4	–	Sell	-11,837	Closed	-$59K	–	1835
2020 Q3	$59K	Sell	11,837 -855	-7%	-$6.22K	﹤0.01%	1639
2020 Q2	$102K	Buy	+12,692	New	+$112K	﹤0.01%	1243
2019 Q1	–	Sell	-13,174	Closed	-$33K	–	509
2018 Q4	$33K	Buy	+13,174	New	+$44.8K	﹤0.01%	543

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

HRT Financial's AVDL Position: Q1 2026 in Review

HRT Financial sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 117,259 shares — an estimated $2.53M sold.

HRT Financial first reported a position in AVDL in Q4 2018 and held it in 8 quarters. The position peaked at $2.53M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

HRT Financial reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 117,259 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.53M.
HRT Financial first reported a position in Avadel Pharmaceuticals in Q4 2018 and held it in 8 quarters.
HRT Financial's Avadel Pharmaceuticals position peaked at $2.53M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.